Abstract: Provided herein are methods for the production of glycopyrronium tosylate and glycopyrronium tosylate compositions. Also provided herein are compositions useful in the production of glycopyrronium tosylate. Additionally provided herein are glycopyrronium tosylate compositions. Glycopyrronium tosylate is useful for the treatment of, among other conditions, hyperhidrosis.

Abstract: Provided herein are methods for the production of glycopyrronium tosylate and glycopyrronium tosylate compositions. Also provided herein are compositions useful in the production of glycopyrronium tosylate. Additionally provided herein are glycopyrronium tosylate compositions. Glycopyrronium tosylate is useful for the treatment of, among other conditions, hyperhidrosis.

Abstract: Provided herein are methods for the production of glycopyrronium tosylate and glycopyrronium tosylate compositions. Also provided herein are compositions useful in the production of glycopyrronium tosylate. Additionally provided herein are glycopyrronium tosylate compositions. Glycopyrronium tosylate is useful for the treatment of, among other conditions, hyperhidrosis.

Abstract: Provided herein are methods for the production of glycopyrronium tosylate and glycopyrronium tosylate compositions. Also provided herein are compositions useful in the production of glycopyrronium tosylate. Additionally provided herein are glycopyrronium tosylate compositions. Glycopyrronium tosylate is useful for the treatment of, among other conditions, hyperhidrosis.

Abstract: Provided herein are methods for the production of glycopyrronium tosylate and glycopyrronium tosylate compositions. Also provided herein are compositions useful in the production of glycopyrronium tosylate. Additionally provided herein are glycopyrronium tosylate compositions. Glycopyrronium tosylate is useful for the treatment of, among other conditions, hyperhidrosis.

Abstract: Provided herein are methods for the production of glycopyrronium tosylate and glycopyrronium tosylate compositions. Also provided herein are compositions useful in the production of glycopyrronium tosylate. Additionally provided herein are glycopyrronium tosylate compositions. Glycopyrronium tosylate is useful for the treatment of, among other conditions, hyperhidrosis.

Abstract: The present invention relates to a process for obtaining rifaximin ? comprising the following steps: a) reacting rifamycin O with 2-amino-4-picoline in the presence of a solvent mixture comprising water and a solvent selected from methyl isobutylketone, ethylacetate and a water soluble solvent; b) obtaining a rifaximin solution by removing the aqueous phase; c) obtaining rifaximin ? from the rifaximin solution, wherein when the solvent is a water soluble solvent, either methyl isobutylketone or ethylacetate is further added in step a). In another aspect the process of the invention relates to a process for obtaining the crystalline form ? of rifaximin comprising the following steps: i) contacting rifaximin or a rifaximin solution with exclusively ethylacetate, ii) obtaining the rifaximin in crystalline form ? by removing ethylacetate.

Abstract: The present invention relates to a process for obtaining rifaximin ? comprising the following steps: a) reacting rifamycin O with 2-amino-4-picoline in the presence of a solvent mixture comprising water and a solvent selected from methyl isobutylketone, ethylacetate and a water soluble solvent; b) obtaining a rifaximin solution by removing the aqueous phase; c) obtaining rifaximin ? from the rifaximin solution, wherein when the solvent is a water soluble solvent, either methyl isobutylketone or ethylacetate is further added in step a). In another aspect the process of the invention relates to a process for obtaining the crystalline form ? of rifaximin comprising the following steps: i) contacting rifaximin or a rifaximin solution with exclusively ethylacetate, ii) obtaining the rifaximin in crystalline form ? by removing ethylacetate.

Abstract: Provided herein are methods for the production of glycopyrronium tosylate and glycopyrronium tosylate compositions. Also provided herein are compositions useful in the production of glycopyrronium tosylate. Additionally provided herein are glycopyrronium tosylate compositions. Glycopyrronium tosylate is useful for the treatment of, among other conditions, hyperhidrosis.

Abstract: A new crystal form of threo glycopyrronium chloride is useful in pharmaceutical applications.

Abstract: The present invention relates to a new polymorph of Rifaximin, designated ?, and to a process for the preparation thereof. Under certain aspects, the invention also relates to pharmaceutical compositions comprising an effective amount of the polymorphic form ? of Rifaximin and a pharmaceutically acceptable carrier and its uses in the treatment of gastrointestinal conditions.

Abstract: The present invention relates to a new polymorph of Rifaximin, designated ?, and to a process for the preparation thereof. Under certain aspects, the invention also relates to pharmaceutical compositions comprising an effective amount of the polymorphic form ? of Rifaximin and a pharmaceutically acceptable carrier and its uses in the treatment of gastrointestinal conditions.

Abstract: A new crystal form of threo glycopyrronium chloride is useful in pharmaceutical applications.

Abstract: A new process is described for the resolution of racemic verapamil, which allows the desired enantiomer to be obtained in high yields and with high enantiomeric purity. The process uses optically active 2,3-bis[(2-fluorobenzoyl)oxy]butanedioic acid as the resolving agent, and a water/dimethylformamide or water/acetonitrile or water/methanol mixture, as the reaction solvent.

Abstract: The present invention relates to a process for the purification of meloxicam and in particular of the impurity composed of 4-hydroxy-2-methyl-N-ethyl-N?-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide and to meloxicam containing a quantity of less than 0.05% of the above-mentioned impurity (“ethylamide”).

Abstract: Process for the synthesis of cetirizine dihydrochloride, wherein (a) a solution of {2-[4-(?-phenyl-p-chlorobenzyl)piperazin-1-yl]}ethanol in 1-7 volumes, referred to the weight of {2-[4-(?-phenyl-p-chlorobenzyl)piperazin-1-yl]}ethanol, of an organic solvent having a boiling point higher than 90° C. and being chosen from the group consisting of aliphatic, cycloalifatic or aromatic solvents is provided, whereafter (b) per equivalent of {2-[4-(?-phenyl-p-chlorobenzyl)piperazin-1-yl]}ethanol employed, 1-2 equivalents of a metal haloacetate or of haloacetic acid, as well as 3-7 equivalents of an alkaly metal hydroxyde are added to the solution as per (a), providing a reaction mixture, where 0.05-0.3 volumes, referred to the weight of {2-[4-(?-phenyl-p-chlorobenzyl)piperazin-1-yl]}ethanol employed, of water and 0.1-1.

Abstract: A new process is described for the resolution of racemic verapamil, which allows the desired enantiomer to be obtained in high yields and with high enantiomeric purity. The process uses optically active 2,3-bis[(2-fluorobenzoyl)oxy]butanedioic acid as the resolving agent, and a water/dimethylformamide or water/acetonitrile or water/methanol mixture, as the reaction solvent.

Abstract: The present invention relates to a process for the preparation of nateglinide, preferably in B-form, substantially free from the H-form, comprising three steps starting from D-phenylalanine methyl ester or a salt thereof.

Abstract: The present invention concerns a new process for synthesising aminoadamantanes of formula I in which R1 and R2 are identical or different and are H or a straight or branched alkyl group comprising from 1 to 6 carbon atoms, and addition salts thereof with inorganic or organic acids, in particular memantine hydrochloride (1-amino-3,5-dimethyladamantane hydrochloride).

Abstract: The present invention concerns a new process for synthesising aminoadamantanes of formula I in which R1 and R2 are identical or different and are H or a straight or branched alkyl group comprising from 1 to 6 carbon atoms, and addition salts thereof with inorganic or organic acids, in particular memantine hydrochloride (1-amino-3,5-dimethyladamantane hydrochloride).